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Abstract
Background: In recent years inhibitors directed against the epidermal growth factor receptor (EGFR) have evolved
as effective targeting cancer drugs. Characteristic papulopustular exanthemas, often described as acneiform rashes,
are the most frequent adverse effect associated with this class of novel cancer drugs and develop in > 90% of
patients. Notably, the rash may significantly compromise the patients’ quality of life, thereby potentially leading to
incompliance as well as dose reduction or even termination of the anti-EGFR therapy. Yet, an effective
dermatologic management of cutaneous adverse effects can be achieved. Whereas various case reports, case series
or expert opinions on the management of EGFR-inhibitor (EGFRI) induced rashes have been published, data on
systematic management studies are sparse.
Methods: Here, we present a retrospective, uncontrolled, comparative study in 49 patients on three established
regimens for the management of EGFRI-associated rashes.
Results: Strikingly, patients’ rash severity improved significantly over three weeks of treatment with topical
mometason furoate cream, topical prednicarbate cream plus nadifloxacin cream, as well as topical prednicarbate
cream plus nadifloxacin cream plus systemic isotretinoin.
Conclusions: In summary our results demonstrate that EGFRI-associated rashes can be effectively managed by
specific dermatologic interventions. Whereas mild to moderate rashes should be treated with basic measures in
combination with topical glucocorticosteroids or combined regiments using glucocorticosteroids and antiseptics/
antibiotics, more severe or therapy-resistant rashes are likely to respond with the addition of systemic retinoids.
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Background
In recent years inhibitors directed against the epidermal
growth factor receptor (EGFR) have evolved as effective
cancer-targeting drugs [1]. These drugs include mono-
clonal anti-EGFR antibodies, such as cetuximab or pani-
tumumab, as well as small molecule EGFR tyrosine
kinase inhibitors, such as erlotinib or gefitinib. Addition-
ally, current studies report promising results on the clin-
ical effectiveness of drugs that target the EGFR-signaling
cascade, such as the BRAF inhibitor vemurafenib or
MEK inhibitors [2]. Characteristic inflammatory papulo-
pustular exanthemas, often described as acneiform or
rosaceaform rashes, are the most frequent adverse effect
associated with the use of EGFR-inhibtors (EGFRI)
[3-6]. Within the first days to weeks of therapy > 90% of
patients develop these rashes. In the majority of cases
skin lesions initially appear within areas of skin that
bear high densities of seborrheic glands. However, the
rash may progress into other areas, generalize in the
course, or progress into perifollicular xanthoma [7].
Notably, recent studies have demonstrated that rash
appearance and severity are correlated positively with
the anti-tumor effect of the EGFRI [8,9]. Accordingly,
the rash is regarded the best surrogate marker for clini-
cal response to EGFR-targeting drugs [9]. Besides the
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adverse effects, including pruritus, paronychias, infec-
tions, or impressive alterations of eyebrows and lashes
[5,6,10-16]. Another notable aspect of EGFRI-associated
cutaneous adverse effects is the severe radiation derma-
titis following additional radiation therapy [17-20]. How-
ever, radio therapy prior to initiation of EGFRI therapy
may also prevent rash development [21].
Taking into account the broad spectrum and the
potential severity of EGFRI-associated adverse effects, it
is reasonable that these toxicities may significantly com-
promise the patients’ q u a l i t yo fl i f e( Q o L ) ,t h e r e b y
potentially leading to incompliance as well as dose
reduction or even termination of the anti-EGFR therapy.
Hence, effective management regimens are urgently
needed.
Here, we report the results of a retrospective study
designed to compare the effectiveness of established
rash management strategies in EGFRI-associated rash
development.
In our study patients were treated using one of three
rash-management strategies: (1) sole topical anti-inflam-
matory measures (mometason furoate cream); (2) com-
bined topical anti-inflammatory (prednicarbate cream)
and anti-infectious measures (nadifloxacin cream); and
(3) combined topical anti-inflammatory (prednicarbate
cream), anti-infectious measures (nadifloxacin cream) as
well as concomitant systemic isotretinoin therapy. All
have previously been reported to be effective by several
independent case reports and guidelines [5,10,22-25].
After three weeks of treatment, patient rashes were re-
assessed to determine the effectiveness of each strategy.
Methods
Assessment of rash severity
Rash severity was assessed during the initial presentation
to our clinics (Departments of Dermatology, University
Hospital Düsseldorf and Ludwig-Maximilian-University of
Munich) and after three weeks of specific dermatologic
therapy. Rash severity was assessed applying the EGFRI-
induced rash severity score (ERSS or WoMoScore), a skin-
specific scoring system introduced in 2008 [26]. Briefly,
the ERSS is a combined score of the severity of five differ-
ent aspects of the EGFRI-rash (color of erythema, distribu-
tion of erythema, papulation, pustulation and scaling/
crusts), combined with a score based on the extent of
affected facial area and the total body area involved. ERSSs
range from 0 (no skin affection), 1 to 20 (mild), between
20 and 40 (moderate), up to scores exceeding 40 points,
indicating severe cases (Figure 1) [26].
Patient selection criteria
Selection criteria included patients treated with cetuxi-
mab or erlotinib that suffered from EGFRI-associated
rash at the time of referral. The selection was limited to
initial patients and their follow-up visits in the time
frame of March 2007 to October 2009. We enrolled 49
patients who presented with an ERSS of 10 or higher.
The study was approved by the local ethics committees.
Treatment
In stage 1 of the study, 21 patients (ERSS 10.3 to 77.9)
were treated topically with mometason furoate cream
twice daily for three weeks. In stage 2 of the study, 23
patients (ERSS 12.5 to 67.1) were treated topically with
nadifloxacin 1% cream once daily in the morning in
combination with prednicarbate 0.25% cream once daily
in the evening for three weeks as described [22,27]. In
s t a g e3o ft h es t u d y ,f i v ep a t i e n t sw i t ha nE R S S>5 0
received topical nadifloxacin 1% and prednicarbate
0.25% cream in combination with the systemic retinoid
isotretinoin 10 to 20 mg/d for three weeks as described
[25]. Adverse effects of our management strategies were
generally rare and in line with the potential common
adverse effects reported for each drug in the literature.
Statistical analysis
Statistical analysis was performed using the Student’st -
test.
Results
In this study we sought to compare the effectiveness of
established rash management strategies. Therefore, we
first assessed the efficacy of a potent anti-inflammatory
topical glucocorticosteroid with low-atrophogenic poten-
tial [28]. Twenty-one patients (ERSS ranging from 10.3 to
77.9) were treated with mometason furoate cream. Assess-
ment of the ERSS prior to therapy initiation and after
three weeks revealed that the mean rash severity improved
significantly (P = 0.00009) from 45.9 to 27.0 and demon-
strated the efficacy of our approach (Figure 2A).
The second regimen used, a combined approach, which
targets the inflammatory as well as the infectious facet of
the rash. Twenty-three patients (ERSS ranging from 12.5
to 67.1) were treated with nadifloxacin 1% cream, a potent
topical fluoroquinolone antibiotic with a broad-spectrum
activity against gram-positive and gram-negative bacteria,
as well as the topical glucocorticosteroid prednicarbate
0.25% cream as described previously [24]. Assessment of
the ERSS revealed that the mean rash severity improved
significantly (P = 0.03) from 30.9 to 24.8 after three weeks,
demonstrating the efficacy of our approach (Figure 2B).
Finally, we included the retinoid isotretinoin that
represents a standard option for the treatment of
papulo-pustular skin diseases like acne or rosacea [4,29].
Moreover, isotretinoin has been reported to be effective
in the management EGFR-antagonist rashes [5,25]. Five
patients, which presented with severe ERSS of > 50 or
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1% cream, prednicarbate 0.25% cream, and systemic iso-
tretinoin (10 to 20 mg/day) [5,25]. Interestingly, these
severely affected patients significantly improved during
isotretinoin treatment (P = 0.015) and demonstrated on
average a reduction of the ERSS from 59.2 to 43.8 after
three weeks of therapy (Figure 2C).
All results are summarized in Table 1.
Discussion
Today, there is a broad variety of independent case
reports and guidelines on different options for the man-
agement of EGFRI-associated rashes [5,22-25]. Yet, stu-
dies that compare different therapeutic regimens and
Figure 1 Severity of EGFRI-induced papulopustular rashes. Rash severity was assessed using the EGFRI-induced rash severity score (ERSS).
ERSSs may range from 0 (no skin affection), over (A) 1 to 20 (mild), (B) 20 to 40 (moderate), up to (C) scores exceeding 40 points, indicating
severe cases.
Gerber et al. European Journal of Medical Research 2012, 17:4
http://www.eurjmedres.com/content/17/1/4
Page 3 of 7Figure 2 Significant improvement of rash severity under specific dermatologic measures.( A) Topical mometason furoate cream
significantly (P = 0.0009) improved the severity of the skin rash (ERSS) in patients treated with EGFRI after three weeks. (B) A combined topical
regimen with prednicarbate cream and nadifloxacin cream significantly (P = 0.03) improved the ERSS in patients treated with EGFRI after three
weeks. (C) A triple therapy with topical prednicarbate cream, topical nadifloxacin cream and systemic isotretinoin significantly (P = 0.015)
improved the ERSS in patients treated with EGFRI after three weeks. Statistical analyses were performed applying the Student’s t-test.
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Accordingly, we conducted a comparative analysis of the
clinical efficacy of different EGFRI rash management
strategies that target the inflammatory and/or the infec-
tious characteristics of the rash. Notably, our results
demonstrate that all approaches were effective and sig-
nificantly reduced the severity of the rash over a period
of three weeks.
The statistically most significant effects were achieved
with topical mometason furoate cream (P = 0.00009),
followed by topical prednicarbate cream plus nadifloxa-
cin cream plus systemic isotretinoin (P =0 . 0 1 5 )a n d
finally topical prednicarbate cream plus nadifloxacin
cream (P = 0.03). However, statistical comparison of dif-
ferent therapy regimen is limited due to variations in
patient numbers and rash severity in each of the three
test groups before therapy. Topical mometason furoate
achieved the highest mean ERSS-reduction with 18.9
points, followed by topical prednicarbate cream plus
nadifloxacin cream plus systemic isotretinoin with 15.4
points and topical prednicarbate cream plus nadifloxacin
cream with 6.1 points. Moreover, topical mometason
furoate was the only therapy that resulted in a complete
resolution of all rash symptoms in one patient. Yet, it
must be noted that statistical significance is highly
dependent on the number of patients included in each
group, and because the ERSS system was designed with
a non-linear affected-area scale emphasizing minor var-
iations in mild patients with face involvement only [26].
Mometason furoate alone appeared to be more effec-
tive than prednicarbate plus topical nadifloxacin. How-
ever, mometason furoate is the more potent
glucocorticosteroid (class III) as compared to prednicar-
bate (class II) and therefore represents a higher risk of
inducing steroid-associated adverse effects, such as skin
atrophy [30]. Nevertheless, it is questionable, whether
these adverse effects may play a role in the short-term
treatment of EGFRI rashes, as inflammatory skin lesions
have been shown to slowly regress even without therapy
in the course of sustained EGFRI-therapy. Topical nadi-
floxacin was administered to target the infectious com-
ponent of the rash [10]. Future studies may analyse the
efficacy of a combination of topical momentason furoate
plus nadifloxacin.
With regard to the variation in significance and over-
all efficacy of the different approaches, it must be noted
that we compared three somewhat heterogenous patient
groups. Whereas patients with varying ERSS were ran-
domly subjected to therapies with topical mometason
furoate or topical prednicarbate cream plus nadifloxacin
cream, the addition of systemic isotretinoin was limited
to patients that were severely affected and presented
either with a very high ERSS (> 50) or patients that
were referred to our clinics due to rashes that were
therapy-resistant to other approaches (such as topical
antibiotics or topical glucocorticosteroids). Accordingly,
effects observed for systemic isotretinoin may not have
been as dramatic when compared to sole topical predni-
carbate plus topical nadifloxacin or topical mometason
furoate.
With regard to study design, it may be criticized that
we did not compare the tested conditions to negative
controls, such as a subgroup of EGFRI patients whose
rash was left untreated for the study period. Yet, an
untreated or insufficiently managed rash can signifi-
cantly compromise the patients’ QoL and patients
included in our analysis had initially been referred to us
specifically for the treatment of their cutaneous adverse
effects by their treating oncologists.
Notably, all approaches that were analysed in this
study are in line with recent expert recommendations
that suggest an escalating strategy for the management
of the EGFRI rash [5,6,16] with a succession of treat-
ments, as indicated, summarized as follows: intensive
skin care in combination with mild cleansers, followed
by the use of mild (class II) to moderate (class III)
potent topical glucocorticosteroids with low atropho-
genic potential such as hydrocortisone butyrate, predni-
carbate (both class II), methylprednisolone aceponate or
momethason furoate (both class III). In fact, our results
demonstrate a significant efficacy of topical glucocorti-
costeroid monotherapy. Taking into account the high
incidence of bacterial superinfections of the EGFRI rash,
alternative recommendations include the combination of












Mometason furoate cream (2x/d) 21 45.9 27.0 18.9 0.00009
Nadifloxacin 1% cream (1x/d) plus prednicarbate 0.25% cream (1x/d) 23 30.9 24.8 6.1 0.03
Nadifloxacin 1% cream (1x/d) plus prednicarbate 0.25% cream (1x/d) plus systemic
isotretinoin (10-20 mg/d)
5 59.2 43.8 15.4 0.015
Patients with EGFRI-induced rash were treated with three different therapy regimens. All therapies resulted in a significant (P < 0.3) improvement of the severity
of the skin rash (ERSS) after three weeks. Statistical analyses were performed applying the Student’s t-test.
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or antiseptics with low cytotoxic potential [31]. Recent
studies report infections at the sites of dermatologic
adverse effects in 38% of EGFRI rash patients. A detailed
microbiologic analysis of these cutaneous infections
identified Staphylococcus aureus in 59.5% of the cases
[10,32]. Nadifloxacin is a potent topical fluoroquinolone
antibiotic hence representing a probable candidate to
target superinfections in EGFRI rash patients. In fact,
we could show that the combination of nadifloxacin 1%
cream and prednicarbate 0.25% cream significantly
improved rash severity. In this context the management
of cutaneous infections is also likely to exert protective
effects regarding the aggravation of skin inflammation as
infectious agents may trigger inflammatory rash progres-
sion by means of “Koebnerization” [33]. Systemic isotre-
tinoin, finally, is recommended for the management of
severe EGFRI rashes of rashes that do not respond to
other therapies [23]. Hence, in our study, patients with
an ERSS > 50 were subjected to a combined manage-
ment approach with nadifloxacin 1% cream and predni-
carbate 0.25% cream as well as systemic isotretinoin
[25]. Our results demonstrate that even severe rashes
can be improved significantly by this approach. Yet, is
must be noted that the use of systemic isotretinoin in
EGFRI patients is controversial, since potential antagon-
ism of the anti-tumor effect of the EGFRI is possible,
although this has not been investigated systematically
yet. Nevertheless, similar arguments may be proposed
for any systemic approach, such as the administration of
oral tetracyclines as rash prophylaxis [34,35].
Conclusions
In summary our results demonstrate that EGFRI-asso-
ciated rashes can be effectively managed by specific der-
matologic interventions. Whereas mild to moderate rashes
should be treated with basic measures in combination
with topical glucocorticosteroids or combined regiments
using glucocorticosteroids and antiseptics/antibiotics,
more severe or therapy-resistant rashes are likely to
respond with the addition of systemic retinoids. Additional
options include systemic antibiotics or systemic glucocor-
ticosteroids. Finally, novel approaches have been proposed
to abrogate EGFR-inhibition specifically in the skin. One
such option is the ligand-independent activation of the
EGFR by topical application of vitamin K analogues, such
as vitamin K1 or vitamin K3 (menadione) [36-39]. Yet,
additional systematic studies are urgently needed to quan-
tify and compare the effectiveness and adverse effects of
EGFRI rash-management strategies.
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